Lewis Pharmaceutical Information, Inc. announces the U.S. Patent Office has granted Patent No. US 10,777,322 B2 to a patient-centric system and platform called Comprehensive Medication Analysis. The software enables a customized analysis of a patient’s health conditions for assessing the appropriateness of an ordered treatment.
Among the purposes of CMA are saving lives, preventing adverse drug reactions, and saving scarce healthcare dollars, said officials. CMA makes this possible by discovering potentially dangerous drug combinations and providing immediate alerts of possible adverse drug reactions. The analysis immediately yields a numerical value, designated as the Patient Profile Relative Safety Rating, with higher values to indicate less-safe patient medication profiles. The result should be safer and more cost-effective use of prescription drugs, said officials.
Jim Lewis, CEO of Lewis Pharmaceutical Information, Inc., has been a practicing pharmacist for over 51 years, currently employed at Parkridge Medical Center. “We have created software that has the potential to improve the quality of medical care,” said Mr. Lewis. “There are millions of pages of research documenting detailed facts about every medication the FDA has approved. The problem has been the absence of a method to deliver critical information to the prescriber as he or she orders a medication for a patient. We believe Comprehensive Medication Analysis is the first step in solving that problem.
“Our long-term goal is to make this software available to every hospital, prescriber and patient in the world,” Mr. Lewis says.